We would like to update you on the decision made regarding the review of the existing guidance on Leukaemia (chronic myeloid) – imatinib (no. 70). The Institute was proposing that it is appropriate for the review to go ahead.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as Appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. We have therefore scheduled an update to the guidance to start in late November 2009 following the MTA process.

The review will include the clinical and cost effectiveness of dose escalation.